Nureca Limited (NSE:NURECA)
India · Delayed Price · Currency is INR 285.00
-2.85 (-0.99%)
Feb 19, 2026, 3:29 PM IST
Nureca Revenue
Nureca had revenue of 396.42M INR in the quarter ending December 31, 2025, with 49.80% growth. This brings the company's revenue in the last twelve months to 1.43B, up 51.01% year-over-year. In the fiscal year ending March 31, 2025, Nureca had annual revenue of 1.10B with 19.29% growth.
Revenue (ttm)
1.43B
Revenue Growth
+51.01%
P/S Ratio
1.92
Revenue / Employee
8.38M
Employees
171
Market Cap
2.75B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.10B | 177.33M | 19.29% |
| Mar 31, 2024 | 919.28M | -193.95M | -17.42% |
| Mar 31, 2023 | 1.11B | -1.44B | -56.44% |
| Mar 31, 2022 | 2.56B | 420.94M | 19.72% |
| Mar 31, 2021 | 2.13B | 1.14B | 114.69% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 568.09B |
| Cipla | 279.67B |
| Apollo Hospitals Enterprise | 242.15B |
| Divi's Laboratories | 103.14B |
| Nectar Lifesciences | 16.70B |
| Valiant Laboratories | 2.03B |
| Bafna Pharmaceuticals | 1.47B |
| Lyka Labs | 1.30B |
Nureca News
- 11 months ago - Nureca shares jump over 3% as Dr Trust & Dr Physio gear up to launch on Swiggy Instamart - Business Upturn
- 1 year ago - Nureca shares surge 6% after company signs distribution agreement - Business Upturn